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Executive Summary 
A cluster of new techniques to modify the genomes of organisms has captured the attention of 
scientists, other experts and the specialised press. The techniques, commonly referred to as Genome 
Editing, have spread rapidly throughout the life sciences. Many suggest that they offer revolutionary 
new applications. 
Prominent scientists, social scientists and policy organisations have called for public discussion of 
the ethical, societal and environmental dimensions of Genome Editing. These calls build on historical 
experience with biotechnologies, which recognises that debate is vital for the development and 
successful deployment of novel science, technologies and innovations in democratic societies. This 
debate must be connected to policy, either through direct participation of diverse public groups or 
through broad-ranging expert representatives. 
However, with respect to Genome Editing, it is not clear to what extent calls for debate have been 
acted upon or how they might interface with existing forms discussion in the life sciences. The 
Wellcome Trust is currently funding research to map Genome Editing and public discussion in 
human health contexts. This document is complementary and begins a preliminary mapping of 
public discussion and engagement of Genome Editing in non-human contexts. 
The review takes a broad perspective of public discussion to identify both formal and informal 
spaces. This includes parliamentary inquiries, attitude surveys and Public Dialogues but also news 
reporting, search frequencies, social media spread and physical public events.  
This work's headline finding is that whilst non-human Genome Editing is attracting significant 
attention from technical and policy experts, there are few indications of any substantial public 
discussion of the topic. Further, much of the formal public debate (engagement activities, and 
attitude surveys) has revolved around human Genome Editing as opposed to its applications in non-
human animals, plants and microbes. This suggests that non-human Genome Editing is a ‘technical 
category’ but not a ‘public topic’.  
The gap in interest can be explained by considering the ways that topics become matters of public 
interest. Empirical studies of past controversies and recent data from The Royal Society’s Public 
Dialogue on Genetic Technologies emphasise the important of context. Questions about the purpose 
(health, the environment, agriculture), people, distribution of costs and benefits, ownership 
arrangements and geographical locations of use are vital in generating and mediating public 
discussion. Indeed, it is these questions — in addition to those relating to technical risk — that will 
be key matters of concern. The answers to these questions will determine whether an application has 
clear public value. 
Whilst non-human Genome Editing is a technical category there are currently very few publicised 
examples of its use in applications. Thus there remain very few material contexts for discussion to 
develop around and it is unclear how they will build on, or depart from, past engagement with 
   
4 
biotechnologies. However, our data suggest that interest in the topic is rising and will continue to 
track prominent public events. 
The novelty of Genome Editing techniques presents both challenges and opportunities for 
governance. To address these, we draw on the results of the Royal Society Dialogue and past social 
scientific research about emerging technologies to make the following recommendations: 
1. Build Capacity for Public Discussion and Debate.  
Instead of trying to predict how the technology will develop and pre-empt public contestation, 
future initiatives should attempt to build capacity for public discussion about non-human 
Genome Editing and its related applications. There is time to do this. Research suggests that 
public trust in science remains high. There is a new diversity of spaces (e.g. science museums, 
community laboratories) where engagement is taking place. Building a better understanding of 
what happens in these spaces, what other ones there are, and what outcomes come from them 
would be a useful first step. 
2. Connect discussion to decision-making.  
There are actions to strengthen the governance of non-human Genome Editing that can be taken 
now. The first is to begin to identify sites at which decision making can be opened-up. This does 
not necessarily mean making them ‘fully public’ but may mean broadening the kinds of expertise 
that inform them. Such mapping work would also act as a form of horizon scanning for future 
governance of any applications. The second action is to begin to develop new ‘rapid 
methodologies’ that are able to open-up such sites in real-time as and when the need arises — 
while there are numerous examples in the social sciences and humanities, they are often quite 
resource intensive. Taken together, such an infrastructure would complement developments 
proposed in other international contexts. 
3. Hold-open key moments. 
Finally, public discussion of non-human Genome Editing will evolve around particular key 
moments, such as regulatory decisions or newly publicised products. It is in such moments that 
it is especially important, but hard, to discuss and debate new technologies. To date, formal 
methods of discussion have tried to emulate such moments. This approach is useful but limited 
because it means that discussion largely remains contained within an artificial environment. An 
ambitious next step would be to develop the new methodologies necessary to hold-open moments 
for discussion in real-time, when there are often strong pressures to close them down.   
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1. Introduction and problem space 
This report reviews public discussion about Genome Editing in non-human organisms1. Its primary 
goal is to provide a preliminary baseline regarding the kinds of public discussion about, and 
interactions with, a development in biotechnology with societal significance. 
The term ‘Genome Editing’ is shorthand for a cluster of new scientific techniques that make it 
possible to make changes at specific sequences of DNA. The technologies are applicable to a wide 
range of plants, microbes and animals, including humans. It has been long been possible to 
deliberately change the genomes of organisms using techniques from molecular biology but Genome 
Editing techniques such as CRISPR-Cas9 make it much simpler, predictable and cheaper than 
before.  
Thus, Genome Editing has been lauded as revolutionary, attracting a significant amount of attention 
from scientists, technologists and policy makers. As of March 2018, NCBI PubMed, a search engine 
for the life sciences, holds 8,563 articles on CRISPR, the main Genome Editing technique2. Gateway 
to Research, the UK public research portfolio analyser, returns 128 distinct projects making use of 
the techniques representing an investment of roughly £55m3. One recent global business forecast 
suggests that Genome Editing-based technologies will reach a market value of around $6bn by 
20224. That most of these articles, grants and valuations have been created in the past two years – 
6,000 articles have been published since 2016 – gives an indication of the speed at which Genome 
Editing has spread throughout the life sciences. 
The buzz surrounding Genome Editing is common to other emerging technologies. Emerging 
technologies are characterised as having the potential to be technically and societally disruptive but 
also unpredictable in terms of how they might be disruptive, that is how they might embed within 
science and society5. It is common for such developments in the contemporary life sciences to be 
accompanied by pleas for public debate6; Genome Editing is no different. Amidst the buzz, calls for 
public discussion are audible from prominent scientists, company directors, social scientists and 
science policy organisations such as the National Academy of Sciences and the Nuffield Council on 
Bioethics. In February 2017, Venki Ramakrishnan, President of the Royal Society, used his speech at 
the AAAS congress to call for public debate about Genome Editing7. To contribute to this debate, the 
Royal Society ran a public dialogue in the autumn of 2017 to explore public views on genetic 
technologies and their potential applications8 
It is important to tease out the motivations driving these calls: each group will have different interests 
at stake when calling for debate and there are different ideas of what such debate entails9. However, 
the most recent report published by the European Academies Science Advisory Council provides a 
good indication of the status quo regarding the need for public engagement around Genome Editing 
and other emerging technologies10. It concludes with the following recommendation:  
“There has to be trust between scientists and the public, and, to build trust there has to be 
public engagement. As observed in the previous chapters, stakeholders (such as patients, 
clinicians, farmers, consumers and NGOs) need to be involved in discussions about risk and 
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benefit, and scientists need to articulate the objectives of their research, potential benefits and 
risk management practices adopted. This is not a special responsibility for genome 
researchers, as all scientists have the responsibility to be open and candid about their work. 
There is need for additional social science and humanities research to improve public 
engagement strategies.” 
Previous research and experience governing emerging technologies has shown that they need to be 
developed in ways that are ethical, safe and accountable, that deliver meaningful public value and 
that foster public trust in democratic institutions 11 . Past experience in Britain suggests public 
deliberation and discourse has a vital role to play in developing effective governance arrangements 
and the nation has developed significant institutional expertise in developing such arrangements12. 
To date, attention has focused largely on the use of Genome Editing in humans. For instance, in 2015 
an international summit produced a consensus statement on human Genome Editing. This was 
followed by a consensus study by the US National Academies of Sciences, Engineering, and Medicine 
into the ethics and governance of human Genome Editing, published in 2017. However, Genome 
Editing techniques span virtually all domains of bioscience and biotechnology that rely on altering 
genetic sequences. In today’s landscape, this means their envisaged uses in both scientific research, 
as tools, and in developing new technologies or commercially-valuable processes are widespread. It 
is therefore vital that non-human applications are considered.  
In the UK, the Nuffield Council on Bioethics recently concluded an initial study on the ethics of 
Genome Editing and is undertaking follow up studies on human Genome Editing and Genome 
Editing in livestock. The Wellcome Trust is currently funding public engagement on Genome Editing 
as applied to human health and medicine through the Genome Editing Public Engagement Synergy 
with the National Coordinating Centre for Public Engagement13. This review complements the above 
work by providing baseline information about public discussion of, and public engagement with, 
Genome Editing in non-human contexts. 
1.1. Questions and review structure 
Using a rapid analysis of publicly-available published material, this review asks three questions: 
1. What discussion of Genome Editing exists in the public sphere and amongst which 
groups? 
2. What information is there regarding public attitudes to and engagement with Genome 
Editing techniques and their applications? 
3. What challenges and opportunities does this public baseline offer for the governance of 
Genome Editing? 
The remainder of the report is structured to follow these questions: Section Two identifies significant 
sources of public discussion around Genome Editing; Section Three analyses the content of that 
discussion; and Section Four considers the results of this analysis for the governance of non-human 
Genome Editing, particularly regarding the potential role of public engagement therein.  
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Box: What is Genome Editing? 
 
This report uses the term ‘Genome Editing’ to refer to a cluster of scientific techniques that are used 
to make changes to the genetic sequences of organisms. This cluster includes, but is not limited to, 
techniques such as CRISPR-Cas9, TALENs, and Zinc Fingers. Genome Editing works as follows: 
First a guide (usually designed by scientists) identifies a particular sequence of DNA. An enzyme (a 
nuclease) then breaks both strands of the DNA. This break will be automatically repaired by the cell, 
but it also allows modifications to the DNA sequence to be made14.  
It has long been possible to make deliberate genetic modifications and Genome Editing is part of this 
lineage15. However, Genome Editing is generally cheaper, faster and more predictable than previous 
methods16. These features have captured the attention of scientists – in 2015 CRISPR was awarded 
‘breakthrough of the year’ by the journal Science – but also social scientists, companies, policy 
makers and the media. 
Because so many biological applications involve the modification of DNA and because Genome 
Editing promises to make this easy, hope has built for a wide range of new non-human 
biotechnologies. Many goals are longstanding, such as the treatment of genetically transmitted 
disease, modifying crops to increase yield or drought tolerance, or producing biofuels from microbes 
or algae. However, Genome Editing has allowed other hypothetical ideas to move closer to reality: 
one is developing ‘Gene Drive’ technologies to control mosquito populations. These ideas raise 
fundamental questions for governance as, for example, their development requires large-scale 
deliberate release of Genetically Modified Organisms into the environment. 
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2. Public discussion of non-human Genome Editing 
The introduction of this review drew attention to the prominence of calls for public discussion and 
participation surrounding Genome Editing. This section is concerned with two questions: First, what 
are the main spaces for public discussion of non-human Genome Editing? Second, who is involved 
in these discussions? To answer these questions the review draws on news reporting, social media, 
grey literature (e.g. policy reports) and publicly-listed events. These data were identified through 
systematic review methodologies, detailed in the appendix. 
The data indicate that public discussion is largely invited and occurring between technical experts, 
organisations and governing bodies. Informal discussion – that is not ‘invited’ – is limited and there 
is relatively low diffusion of the term ‘Genome Editing’ into public discourse. This is, however, rising. 
Box: Formal and informal discussion 
Throughout the report we make a distinction between 'formal' and 'informal' types of public 
discourse17. We do this to begin to capture a broad range of discussion. The former is characterised 
as spaces where discussion is invited, usually by politicians or science policy organisations. This 
includes parliamentary inquiries and government-commissioned public dialogues. The latter, 
‘informal discussion’ is closer to 'naturally occurring' or self-organising discussion, which includes 
media reporting, public lectures and discussion on social media. It is important to recognise that the 
two categories are not completely discrete. An obvious example of this is that the publication of policy 
reports can be events in themselves, driving news reporting and upticks in activity on social media. 
2.1. Formal spaces 
In the UK there have been four major policy reports with relevance to the topic of non-human 
Genome Editing18. Each report has a public consultation period, meaning that they are able act as 
pockets of public debate. Collectively, the four consultations contain over 240 submissions from a 
wide range of stakeholders (Figure One). The vast majority of submissions came from experts, 
policymakers, civil society stakeholders and representing organisations or others’ members of 
society’s views. 
During the 2000s, Britain institutionalised a mechanism for invited public engagement with science 
and technology in the form of the ‘Public Dialogues’19. The term Public Dialogue is formally defined 
by Sciencewise and the Department for Business, Energy and Industrial Strategy, and Public 
Dialogues have typically taken the form of discrete large-scale projects20. To date, there has been one 
Public Dialogue on non-human Genome Editing, organised by the Royal Society. This dialogue ran 
from September to October 2017 and convened 90 members of the British public in Edinburgh, 
London and Norwich to discuss different applications of genetic technologies, including in livestock, 
insects, crops and industrially-useful microbes.  





Figure One: 172 groups have submitted evidence to policy reports and parliamentary inquiries 
 
 
Figure Two: Counts of articles reporting on different aspects of Genome Editing in the UK press (1 
March 2016 - 5 May 2018). As is common, the vast majority of these articles follow the publication 
of scientific articles or policy reports.  















Figure Three: Relative Google Trends frequencies of different search terms in the UK between May 
2013 and May 2018. The large peak for climate change relates to the Paris Agreement. CRISPR 
(Sky Blue in both diagrams) is used as the indicative search term for Genome Editing as the term 
with the highest relative hits (vs. e.g. Genome Editing, Gene Edit etc.).  
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A final identifiable invited space is public attitude surveys. Three have been conducted. The first, 
consulting 2084 people, was commissioned by Bayer Crop Science and run by Populus on the topic 
of crop science and agriculture. The second was conducted by staff at the website 
Whatisbiotechnology, receiving 570 responses with 126 from the UK. The most recent survey, of 
2061 people, was conducted as part of the aforementioned dialogue to validate its findings. While 
these surveys reach comparatively large proportions of the population, in their own right they 
provide little opportunity for debate and their methodologies are not transparent, making them 
difficult to interrogate or replicate. In this respect it is notable that to-date Eurobarometer, which 
does have consistent methodology and longitudinal power regarding public attitudes to emerging 
technologies, has not included any questions regarding non-human Genome Editing21. 
2.2. Informal spaces 
To supplement these invited instances of public discussion we have conducted pilot analyses of off- 
and on-line media sources. These analyses indicate that the term ‘Genome Editing’ has little diffusion 
into the public domain: as a proportion of total material available, Genome Editing remains low. 
Further, there is little substantive discussion of non-human Genome Editing. Because of the limited 
scope of this review this finding is tentative. It does, however, echo findings of the Progress 
Educational Trust that diffusion of a language of Genome Editing beyond expert communities is low. 
In the past two years, UK national newspapers have published 55 articles on the topic of non-human 
Genome Editing. (To provide a comparison there have been roughly 882 articles relating to Stem 
Cells in the same period.) The vast majority of these articles report a scientific discovery and contain 
little in the way of discussion about Genome Editing or its societal context. Without a full analysis, it 
is difficult to establish a clear sense of how the technology might be framed by such outlets, and in 
particular how existing debates about genetic modification will influence public trust and attitudes 
in the future. A cursory analysis indicates differences in language use between human and non-
human. There is comparatively more, and deeper, coverage in the specialist online press, such as 
Wired, and this often contains more discussion around the technology. 
Google Trends provides relative search activity for terms and topics and with care is able to 
supplement public attitude surveys. The service does not provide indications of the constituencies 
conducting the searches, meaning that without significant effort it is difficult to directly infer which 
populations of actors are searching. However, as Figure Three indicates, in the UK Genome Editing 
currently has a low relative interest in relation to other scientific issues, such as Artificial Intelligence 
and Climate Change. In relation to other biotechnologies, however, topics such as CRISPR have 
relatively higher, and growing, search activity.  
Discussion on Twitter is also limited and largely contained within scientific communities. Tweets 
related to Genome Editing predominantly originate from business and/or industry sites. Many of 
these tweets are re-tweets of other scientists or companies. YouTube provides more in-depth 
information and discussion than twitter or the mainstream news.  Searching for “gene editing” on 
YouTube revealed 278,000 matches and searching for “Genome Editing” revealed 87,000 matches.  








Figure Four: Locations and counts of publicly listed events on non-human Genome Editing in the 
UK  
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The most-viewed videos are provided by digital media/news companies and online news sites, 
research institutions and science bodies, and public talks. The most watched YouTube video has 8.6 
million views22, all others having views below 1.3 million. 
We have supplemented this information with past and future events listed on the website Eventbrite 
(Figure Four). Globally, in the English-speaking world, there have been just over 300 events listed 
on the topic. The vast majority of these are in the United States and are public lectures. In the UK, 
38 events have been held or are scheduled. They take the form of debates on the ethics of Genome 
Editing, outreach lectures, and more technical public events such as DIY biology events. Events are 
largely clustered around scientific institutions. 
The sparse presence non-human Genome Editing in the public domain should not be taken as a lack 
of interest. In the most recent Royal Society survey, 70% of respondents said they would be interested 
to know more about the topic. A key finding of its associated Dialogue is that members of the public 
would welcome increased communication and involvement in the governance of Genome Editing. 
This finding has been replicated in a wide range of participatory governance processes: while 
resource intensive, substantive citizen participation is central to robust governance in contested 
situations23. 
3. Analysis of public discussion 
This section provides an interpretative analysis of public discussion on non-human Genome Editing. 
It focuses on three aspects. First, what lessons regarding public perspectives on non-human Genome 
Editing can be taken from the formal sites of discussion? Second, what insights can be derived from 
the informal spaces, especially the high scientific interest and comparatively low media reporting? 
Finally, we consider the gaps that remain in our knowledge about public discussion of the topic, 
which may need to be addressed moving forwards. 
3.1. Conditional support 
Studies on public hopes, aspirations and concerns relating to non-human Genome Editing have been 
published in five countries (New Zealand, Germany, The Netherlands, Japan and the United 
States) 24 . There are distinct cultural values between national populations in relation to 
biotechnology25, meaning that the specific findings should be compared with caution. However, 
these studies repeatedly find that the interests of citizens in these studies go beyond questions of 
technical risk; they are also concerned with questions of the perceived benefits of a technology, trust 
in actors, equity and questions of bioethics26. 
The Royal Society Dialogue on Genetic Technologies was conducted between July and November 
2017. Following advice from the Nuffield Council on Bioethics, it asked participants in three UK 
locations to generate a series of social challenges facing Britain today and then locate Genome 
Editing technologies within them. In doing so, the dialogue replicated findings from numerous 
previous public dialogues on emerging technologies27. It demonstrated: 
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Conditional support for Genome Editing as one method in a portfolio of approaches. In the most 
general terms, Genome Editing was seen as valuable to pursue and research into it should be 
supported. There are caveats to this support, most obviously that research into Genome Editing 
should not ‘crowd out’ alternative fields of research, forms of innovation and ways of addressing 
societal challenges. 
Prioritise uses of Genome Editing with clear public benefit. Hypothetical scenarios that offered 
improvements to human health or animal welfare were ranked as more worthwhile than those which 
offered improvements in food production efficiency. Applications where there was no analogous 
alternative were ranked over those where there were existing alternative solutions. For instance, 
despite environmental risk, the use of Genome Editing to remove vector populations was ranked 
over the use of Genome Editing to increase the production efficiency of fish, but only under not-for-
profit business models. 
Assessments based on more than just risk. In evaluating the use of different hypothetical Genome 
Editing applications, participants emphasised that questions of safety should be a priori addressed. 
As important, however, are the following criteria: 1) Prioritising collective wealth over private or 
corporate wealth; 2) Prioritising more equitable distributions of costs and benefits amongst humans 
but also animals and the environment; 3) Prioritising applications that can lower cost of existing 
products or treatment; 4) Valuing cultural and environmental diversity; 5) Ensuring decision making 
is multidisciplinary, inclusive of citizens and transparent. 
Publicly-funded organisations have a vital role to play. When offered a range of potential actors, 
participants ranked publicly funded scientists, professional societies, and charitable foundations as 
most the trustworthy bodies to provide information and develop and govern Genome Editing. 
(Businesses, privately funded scientists and charities were less trusted) This suggests there is no 
blanket dismissal of expertise and implies an important role for publicly-funded bodies in driving 
public discussion about Genome Editing. 
3.2. Genome Editing is an emerging public topic 
This review departures from an observation that a significant amount of attention is focused toward 
Genome Editing: There is a substantial amount of published scientific literature, a significant 
amount of funding, and a significant number of calls for public debate. Our data, however, indicate 
that this attention is largely contained within scientific and policy communities. Discussion amongst 
lay publics, if it occurs, appears to be predominantly invited and in formal spaces (e.g. Public 
Dialogues, Attitude Surveys). This suggests that Genome Editing (and non-human Genome Editing 
therein) may be a defined technical category but is not yet a clear public topic28. The significance of 
this insight is considered below. 
Technical categories matter for science and for the regulation of products because it takes a great 
deal of specificity, skill and resources (e.g. reagents, equipment, software) to ‘do’ Genome Editing in 
a way that can produce viable outcomes. Indeed, there remain technical questions about the specific 
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conditions under which genome editing works as expected29. It is scientifically important to be able 
to repeat these processes and regulatory processes frequently rely on these stable definitions. In 
Europe, for instance, early discussions raised the possibility that non-human Genome Editing may 
challenge or be exempt from existing regulation on the deliberate release of genetically modified 
organisms (GMOs) when no exogenous DNA is used in the editing process. If a plant is ‘edited’ using 
only sequences of DNA found in that organism, it is likely that it will not be regulated as a GMO30.  
Some scientists, policy makers and companies emphasise the need to distinguish between Genome 
Editing and other genetic engineering techniques 31 . Similarly, the Progress Educational Trust 
emphasises the importance of clearly communicating the distinctions between different kinds of 
Genome Editing and their uses when communicating to members of the public. These activities are 
useful. There is lots of evidence to show that citizens are able to gain appropriate technical expertise 
— as citizen scientists, patient activists, or public campaigns — when they wish to take part in 
democratic processes and building clarity through, for instance, common metaphors and shared 
language is important32. 
The recommendations above are based on the idea of Genome Editing as primarily a technical 
category. As important for governance is to consider how it may develop as a public topic. Here, past 
research into science and technology in public suggests three features are important to pay attention 
to: 
The importance of policy moments. Non-human Genome Editing will be given meaning over an 
extended period of time. However, this will be substantially mediated by particular 'moments' that 
generate significant media, policy and public attention. Perhaps the best contemporary example of 
this is climate change. As visible in Figure One, search interest has built over an extended period but 
spikes appreciably around key events, the most extreme example being the Paris Agreement. 
Genome Editing follows a similar (but much attenuated) pattern, for example with news reporting 
tracking key policy reports, regulatory decisions and scientific advances. Some of these moments 
have already happened or are in motion, such as the European Commissions deliberations about 
regulation of Gene Edited plants or posited field trials of Gene Edited mosquitoes. 
Public topics are more than technical. Second, public topics turn around questions that are more 
than technical. Debate may be conducted in technical terms (as required by policy processes, which 
often have tightly definitions of evidence.) but at its heart will be about political, cultural and social 
issues. Indeed, events such as the Royal Society Dialogue, which give citizens the opportunity to learn 
and interrogate Genome Editing commonly find that these people tend to prioritise concerns around 
the wide range of criteria that determine what roles a technology takes in society and how the relative 
benefits and harms are distributed(fn 31). This means that trying to draw clear and consistent 
boundaries between different kinds of genetic intervention will be a communication strategy with 
limited value. 
Meaning will build around applications. Non-human Genome Editing will be given public meaning 
through the uses to which it is put. This is because the applications of non-human Genome Editing 
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have a material context: constellations of people, organisations, models of ownership, channels of 
communication spaces of debate, as well as the physical properties of any object and the areas it is 
used33. To labour the point a little, it makes little sense to think about Genome Editing as an isolated 
technology: the pertinent questions to ask in humans are different to non-humans because societies 
value these things differently. Similarly, the contexts provided when a purpose is to improve health 
are different to those if the purpose is improving agriculture. Early examples of this phenomenon 
are visible in media and scientific reporting of projects, which tightly couple non-human Genome 
Editing to applications in the world (however speculative they may be). The above discussion of 
policy moments means that the first applications will be extremely important in guiding the 
evolution of non-human Genome Editing as a public topic. 
3.3. Conclusion 
Whilst non-human Genome Editing is a distinct technical category there are currently very few 
publicised examples of its use in applications. Thus there remain very few material contexts for 
discussion to develop around and it is unclear how they will build on, or depart from, past 
engagement with biotechnologies. Our data suggest that interest in the topic is rising, and will 
continue to track prominent public events. 
Findings from the Royal Society Dialogue reinforce the lessons from past Public Dialogues on related 
topics and provide an initial indication as to the factors that members of the public consider to be 
important when governing Genome Editing technologies in a range of contexts. However, it is 
important to remember that such findings are based on discrete, contained settings with hypothetical 
applications rather than non-human Genome Editing as manifested in an actual precedential 
moment. It is incredibly difficult to know how such moments will develop, a point compounded by 
the ubiquity of Genome Editing in the life sciences. In the final section we consider the significance 
of this review for governance and public engagement. 
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4. Lessons for the governance of Genome Editing 
This final section considers the consequences of the landscape of public discussion for future policy 
options. It develops recommendations in response to three questions:  
1. Why promote public discussion of Genome Editing?  
2. When is the right time? 
3. How could discussions be supported? 
In the past three years, Genome Editing techniques have become ubiquitous in the life sciences. The 
pace at which this has happened — and at which developments continue — is rare. That the parties 
developing these techniques are calling for debate about the appropriate ways for them to be used is 
laudable, emphasising how central the notion of public discussion as vital for technology 
development has become for democratic societies; this has not always been the case. 
Such discussions should happen early, while the directions of technological development can be 
readily steered, but it is equally important that they are seen not as obligatory passage points that 
clear the way for applications. Instead, public discussion should be an on-going process to strengthen 
governance34. This is important because there is still significant uncertainty about the social and 
technical trajectories that non-human Genome Editing will take: There is technical uncertainty 
regarding the conditions — in what organisms and with what efficiencies — under which Genome 
Editing will work as expected; There is translational uncertainty regarding the arenas in which 
Genome Editing will be economically viable; And there is social uncertainty about the kinds of groups 
and situations that will form as Genome Editing applications move from the laboratory into the 
world35. 
A 2014 report published by the Government Chief Scientific Advisor convincingly argues that 
substantive public engagement with – and even contestation of – the different possible development 
paths that technology development proceeds down is vital to fostering an ‘Innovation Democracy’36. 
Rethinking public discussion in the service of such an Innovation Democracy would mean providing 
support to self-organising sites of discussion, in the process building civic capacity for engagement 
with non-human Genome Editing. It would also mean experimenting with novel fora and forms of 
public discussion and finding ways to draw publics into the governance of technology 37 . The 
suggestions below complement recent recommendations to develop infrastructure for public debate 
made separately in Nature for a ‘Global Observatory’ and an ‘Infrastructure’ for public 
participation38. 
Recommendation 1: Map and support public discussion and engagement. 
Our analysis suggests that non-human Genome Editing offers an opportunity to develop such an 
approach to public engagement. First, there is an apparent demand on the part of scientists, 
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technologists and science policy experts for public debate and engagement. Second, there is time to 
build capacity for public discussion. 
Perhaps the most important dimension is that there is an inherent diversity to the topic -- the 
contexts of non-human Genome Editing are diverse and so are the spaces for discussion. We have 
drawn attention to a range of media and online fora, but the past twenty years have seen a multitude 
of other spaces for citizens to engage with science and technology. This includes science festivals, 
community labs and citizen science projects 39 . For instance, focusing on energy, one recent 
systematic review identified over 300 individual examples of public discussion and engagement40. 
The authors emphasise the diverse forms of citizenship – including but not limited to campaigning 
publics – within this ecology. Another recent study focusing on citizen science projects has begun to 
unpack different forms of citizen participation in genetics, offering an alternative typology that pays 
attention to levels of openness, the groups participation and the outcomes that follow41.  
Emphasising diversity also draws attention to how little is known about such spaces in the non-
medical biosciences and, vitally, what resources are needed to support the formation of public groups 
within them. Thus, we recommend that any attempt to develop an infrastructure for public 
participation and discussion should be underpinned by a more comprehensive mapping of citizen 
engagement in the spaces that non-human Genome Editing touches on. While there is significant 
uncertainty regarding the future of Genome Editing, developing a topic map based on published 
sources would provide a point of departure to identify any relevant actors. Social scientific 
methodologies such as issue mapping, sentiment analysis and qualitative interviewing, would be able 
to systematically address three key remaining questions: 
1. What public groups are forming and what kinds of citizenship do they produce? 
2. How is Genome Editing being represented in such spaces and by whom? For instance, is 
framed as an object of hope or concern? 
3. To what extent do discussions build on or depart from past experiences with Genetically 
Modified Organisms and other biotechnologies? 
Recommendation 2: Connect public discussion to decision making. 
It is important to consider the motivations driving the calls for public discussion. The social sciences 
frequently distinguish between instrumental, substantive and normative rationales 42 . An 
instrumental rationale drives public discussion but holds it separate from the power to make, or even 
inform, decision-making. This is often coupled to an information sharing mode of action: clearly-
communicating the logic of / evidence for the decision will encourage people to support it. A 
substantive rationale pursues discussion on the basis of feeding in different kinds of knowledge to 
technology development, on the basis of making better decisions about the development of 
technology in particular contexts of use. A normative rationale drives discussion on the basis that it 
is the ‘right’ thing to do in democratic societies43.  
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These rationales can have significant consequences for the form that public discussion of science and 
technology takes and the outcomes that follow44. For instance, in practice much decision making 
power — about, for example, research agendas or product regulation — is separate to the sites of 
public discussion and debate. While the Public Dialogues aim to connect discussion and decision 
making, this is extremely difficult to do and in practice they frequently lean towards instrumental 
rationales that reinforce the separation. That is, they risk viewing public discussion and the groups 
involved as something to be contained – either in time, space or in terms of valid arguments – or 
enrolled in support of a policy or technology45. 
There are credible reasons for this separation — for example, based on ideas about expertise needed 
to discuss scientific proposals — but it is an overly narrow view of the role that public discussion can 
play in the development of non-human Genome Editing. Focusing too-heavily on the protection of 
science from public contestation comes at the expense of empowering external stakeholders – with 
different knowledge, experiences and values – to add value to innovation processes. In a use-case 
that is directly relevant to non-human Genome Editing, social scientists working at the French 
National Institute for Agricultural Research (INRA) have demonstrated how drawing in diverse 
groups can improve the quality of decision-making about the conditions under which technologies 
are developed and in which direction46; that is, the technologies do a better job functioning and the 
science is more likely to be in the public interest. In doing so, the social scientists emphasise that 
such discussion is not a recipe to keep everyone happy – there will always be winners and losers. 
“Rather, it improves the robustness of decisions by taking into account the diversity of world views 
and interests”47. Similar experiences are available in the field of synthetic biology48. 
Thus, we recommend that a clear next step in developing an infrastructure to support discussion of 
non-human Genome Editing is to find ways to connect discussion to decision-making. There are two 
obvious points of integration: 
1. Strategic decision making relating to research funding agendas, especially in light of 
mission-oriented public funding49. 
2. Sites of soft law, such as standard setting and certification processes50,  
Recommendation 3: Develop methods to hold-open policy moments. 
Some contemporary forms of formal discussion recognise the importance of context and try to build 
hypothetical scenarios to help reduce the uncertainty around science and technology. The Royal 
Society Dialogue is both typical and instructive in this regard: In order to contextualise Genome 
Editing, the organisers hooked discussion to a scaffold of hypothetical scenarios involving a range of 
organisms and societal challenges. This helped participants to produce context-specific 
recommendations about the conditions under which Genome Editing applications might be 
acceptable to them.  
However, this is not a case of live policy making and so while useful, the exercise can only partially 
capture the dynamics of such moments. Take the examples of Gene Drive for Health in the Global 
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South. Even in the face of potential unknown environmental risks, the participants within the Royal 
Society Dialogue saw clear value in the application, ranking it higher in priority than applications 
that might seek to improve food production efficiency. However, this assessment was tightly coupled 
to a series of criteria that would help to ensure a strong public interest, namely if the benefits were 
distributed widely, they were deployed for humanitarian purposes and with a not-for-profit 
economic framework. Given the dominant modes of commercialisation and intellectual property 
development surrounding biotechnology it is questionable whether such criteria could ever be met. 
Thus, if this insight from a well-institutionalised mode of public discussion is to be taken seriously, 
there are questions about the potential models of ownership and intellectual property that Gene 
Drive technology – an application of non-human Genome Editing – should be subject to51. A positive 
next step, then, is to find ways to connect up public discussion to decision making during moments 
of live policy making, as and when they emerge. 
This is challenging in part because it is extremely difficult to predict how or when such moments will 
occur naturally: neither technology, governance nor public discussion progress down a clear bright 
path. As this review has noted, each pass through extended periods of stability interspersed with 
more dramatic moments of contestation and change 52 . They are increasingly configured by 
developments in other international contexts53. A second challenge is that during these moments of 
public salience there is often time pressure, reputational risk and differing ideas of what constitutes 
credible expertise, rational argumentation and acceptable forms of evidence54 . These dynamics 
commonly work in concert to provide an intrinsic tendency to close down public discussion and 
appraisal55. And yet, such moments can be important because they set precedents – e.g. when key 
legal rulings are made – or because they allow the airing of contested values and perspectives that 
shape positions for extended periods of time afterwards56.  
There are currently few available methodologies that work against these pressures and hold-open 
moments for discussion and debate in real-time. However, there is expertise within government 
departments and a range of social scientific methodologies that, whilst currently resource and time 
intensive, could be suitable candidates to adapt57.  
The first step in this process is to identify historical examples, live sites and future cases. Thus, a 
systematic mapping of near-term technological pathways, sites of use and sites of governance would 
significantly reduce the uncertainty around non-human Genome Editing58  because it will draw 
attention to the ways in which future applications will interface with existing regulatory regimes, 
ownership models and stakeholder groups. It would identify near-term policy moments in which to 
open-up decision making and live cases — such as Gene Drive technologies — that would form 
productive pilot sites because the coalitions, geographical contexts and envisaged purpose are 
visible. 
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Annex: Review methodology 
This review is based on systematic literature and media searches conducted during March 2018, 
supplemented in May 2018.  
Literature searches 
In order to identify publications and media reporting on the topic of Genome Editing, the following 
set of search strings were used. 
 
It is important to note that the review was commissioned to target public discussion specifically, 
thus our searches explicitly focused on co-occurrence of synonyms for Genome Editing and the 
public, potentially excluding articles focusing solely on regulatory or ethical aspects. 
 
Sources Genome Editing   Public   Discussion 
Academic Literature 
• Web of 
Knowledge 
• Scopus 
• Google Scholar 








































In order to rapidly gauge discussion in the public sphere, we monitored high level and prominent 
social and other media relating to gene technologies. 
4.1.2. Mass media 
A search in Nexis for the terms “genome editing” OR “gene editing” OR “gene drive” OR “CRISPR” 
in the headlines or lead paragraphs of UK national newspaper articles over the past 2 years (1 
March 2016- 5 May 2018). This revealed 298 articles. Reading the headlines only, and removing 
duplicate, excessively short or other non-applicable articles (65) left 233 relevant articles. 120 of 
these articles were specifically related to human gene editing. Searches that cover the whole article 
text with no limit on timeframe produced 1457 results. Media can provide an indication of public 
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discussion. Although excluded because of resources, an in-depth analysis of a comprehensive 
corpus must contain other online sources (e.g., for instance Buzzfeed, Reddit). 
4.1.3. Twitter 
A brief 30-day (January-February 2018) tweet frequency analysis using the search term “gene 
editing” revealed limited twitter discussion about gene editing (13,465 tweets). Specific tweets over 
the months of January and February 2018 containing the terms “gene editing” (on its own, or with 
the additional search terms “public” or “governance”) were explored in more detail to gauge 
information about the publisher, types and content of tweets being disseminated. A more thorough 
and rigorous analysis is recommended, if required, for a more accurate description of the data. 
4.1.4. YouTube 
A YouTube search for “gene editing” AND “public” had 8430 results (“gene editing” had 288,000 
hits). The first 50 results were explored to get a sense of the publisher, types and content of the 
YouTube clips. A more thorough and rigorous analysis is recommended, if required, for a more 
accurate description of the data. 
4.1.5. Hansard 
Searches for gene editing, Genome Editing, genome edited, gene edited and GMO were conducted 
using the UK parliamentary record. Because of the large amount of responses (124 spoken 
references and 17 written statements) reference to GMOs were later excluded, leaving 8 spoken 
references to Genome Editing in the House of Lords and House of Commons. 
Activity review 
Public engagement and science communication activities and events carried out, especially those 
that fall outside formal literature / reporting, were explored. These were identified from 
preliminary literature searches described above and specific searches of Eventbrite. 
4.1.6. Parliamentary inquiry and Nuffield Council on Bioethics evidence analysis 
In order to gauge active parties, written and oral evidence was scraped and collated from four UK 
policy studies relating to non-human Genome Editing: 
1. House of Commons Science and Technology Committee (2015) Inquiry into new plant 
breeding technologies 
2. House of Lords Science and Technology Committee (2016) Genetically Modified Insects 
Inquiry 
3. Nuffield Council on Bioethics (2016) Genome Editing: An Ethical Review 
4. House of Commons Science and Technology Committee (2017) Inquiry into Genomics and 
Genome Editing 
Submissions were coded according to a sector. However, it is important to note that this data is 
messy. E.g. some submissions contained evidence from a range of individuals / organisations in a 
number of different sectors. Some organisations submitted duplicate or supplementary evidence. 
Duplicates were removed, and, if more than one author contributed to the evidence, the evidence 
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was assigned a category relating to the lead author. Because of this, a full mapping is therefore 
recommended. 
4.1.7. Eventbrite 
To begin to gauge self-organising public engagement, we conducted searches of past and future 
events listed on the website Eventbrite. URLs were first extracted from site specific searches of 
Eventbrite using Google and DuckDuckGo. Any event containing the terms CRISPR, Genome 
Editing or Gene Edit were returned. Duplicates were removed, and the resulting URLs were fed 
into a Webscraper to obtain event listing information, organiser, date and location. Data were 
cleaned (e.g. removing false positives) and mapped geographically using Tableau. Further analysis 
of the contents of events is possible, recommended. Analysis should be supplemented with data 
from other publicly listed sites, e.g. Meetup. 
